Literature DB >> 14727261

The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Masanori Matsumoto1, Hideo Yagi, Hiromichi Ishizashi, Hideo Wada, Yoshihiro Fujimura.   

Abstract

A total of 290 Japanese patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) were analyzed with respect to ADAMTS-13 activity and its inhibitor. Twenty-one patients (17 families) had Upshaw-Schulman syndrome, and 12 patients (six families) had familial HUS of undetermined etiology. The number of patients with acquired HUS and TTP was 44 and 213, respectively. In acquired TTP, patients with severe deficiency of ADAMTS-13 activity secondary to the presence of an inhibitor were high responders to plasma exchange, but others were low responders to plasma exchange. The former patients were associated with "idiopathic" TTP, drugs, and pregnancy, and the latter patients with malignancy and stem cell transplantation. Patients with autoimmune disease-associated TTP fit into both groups.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14727261     DOI: 10.1053/j.seminhematol.2003.10.009

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  16 in total

1.  Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience.

Authors:  Moon Ju Jang; So Young Chong; In-Ho Kim; Jee-Hyun Kim; Chul-Won Jung; Ja Young Kim; Ji-Chan Park; Sun Min Lee; Yeo-Kyeoung Kim; Ji-Eun Lee; Sung-Su Jang; Jin-Seok Kim; Deog-Yeon Jo; Dae-Young Zang; Young-Yiul Lee; Ho-Young Yhim; Doyeun Oh
Journal:  Int J Hematol       Date:  2011-02-03       Impact factor: 2.490

Review 2.  Thrombotic thrombocytopenic purpura: recognition and management.

Authors:  Joseph E Kiss
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

3.  National questionnaire survey of TMA.

Authors:  Naomi Ito; Hideo Wada; Masanori Matsumoto; Yoshihiro Fujimura; Mitsuru Murata; Takashi Izuno; Minoru Sugita; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2009-09-18       Impact factor: 2.490

4.  Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.

Authors:  David G Motto; Anil K Chauhan; Guojing Zhu; Jonathon Homeister; Colin B Lamb; Karl C Desch; Weirui Zhang; Han-Mou Tsai; Denisa D Wagner; David Ginsburg
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

5.  A second national questionnaire survey of TMA.

Authors:  Naomi Ito-Habe; Hideo Wada; Masanori Matsumoto; Yoshihiro Fujimura; Mitsuru Murata; Takashi Izuno; Minoru Sugita; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2010-06-05       Impact factor: 2.490

6.  Measurement of ADAMTS13.

Authors:  Han-Mou Tsai
Journal:  Int Rev Thromb       Date:  2006

Review 7.  Pivotal role of ADAMTS13 function in liver diseases.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

Review 8.  Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Kidney Int Suppl       Date:  2009-02       Impact factor: 10.545

9.  Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.

Authors:  Paul Coppo; Michael Schwarzinger; Marc Buffet; Alain Wynckel; Karine Clabault; Claire Presne; Pascale Poullin; Sandrine Malot; Philippe Vanhille; Elie Azoulay; Lionel Galicier; Virginie Lemiale; Jean-Paul Mira; Christophe Ridel; Eric Rondeau; Jacques Pourrat; Stéphane Girault; Dominique Bordessoule; Samir Saheb; Michel Ramakers; Mohamed Hamidou; Jean-Paul Vernant; Bertrand Guidet; Martine Wolf; Agnès Veyradier
Journal:  PLoS One       Date:  2010-04-23       Impact factor: 3.240

Review 10.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.